A Double Blind, Randomized, Placebo Controlled, Multicenter, Dose Finding Study of Oral AEB071 Assessing Psoriasis Area and Severity Index (PASI) Response and a Function of Dose and Treatment Duration (Primary Outcome) in Patients With Plaque Psoriasis.

Trial Profile

A Double Blind, Randomized, Placebo Controlled, Multicenter, Dose Finding Study of Oral AEB071 Assessing Psoriasis Area and Severity Index (PASI) Response and a Function of Dose and Treatment Duration (Primary Outcome) in Patients With Plaque Psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Sotrastaurin (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Planned end date changed from Oct 2010 to Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top